Jul 27,2023

Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023. Management will hold a conference call to review the Company’s second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 27,2023 TOP STORY

Dexcom Reports Second Quarter 2023 Financial Results

DexCom, Inc. reported its financial results for Q2 2023, with revenue growing 25% to $871.3 million on a reported basis, up from $696.2 million in the second quarter of 2022. The company also reported U.S. revenue growth of 21% and international revenue growth of 38% on a reported basis.

View Analyst & Ambassador Comments
Go to original news
Jul 10,2023 TOP STORY

Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes

Better Therapeutics received FDA authorization for AspyreRx™, a prescription-only digital therapeutic (PDT) treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes (T2D). AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices. AspyreRx is expected to launch commercially in Q4 2023?.

REGULATORY FDA

#dtx

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 25,2023

Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share

Better Therapeutics raised $6.7 million through equity offerings to support the launch of AspyreRx™, a prescription-only digital therapy for adults with type 2 diabetes, as a result of the issuance of 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jul 27,2023

One Drop Nominated for 2023 Prix Galien USA Awards

One Drop, a precision health solutions leader, nominated for the 2023 Prix Galien USA Awards in Best Digital Health Solutions category.Prix Galien is widely recognized as the highest accolade for biomedical research and product development in the pharmaceutical, biotechnology, medical technology, and digital health industries. Winners announced on October 26, 2023.

View Analyst & Ambassador Comments
Go to original news
Jul 28,2023

Global Insulin Pen Market Projected to Reach $73.39 Billion by 2028 with Steady CAGR of 5.25% during 2023-2028

The global insulin pen market is expected to reach US$73.39 billion by 2028 with a CAGR of 5.25%, according to the publisher. Smart insulin pens are driving growth, aided by technological advancements and increasing diabetic population. China and Germany are experiencing significant growth in the insulin pen industry. Key players include B. Braun, Eli Lilly, BD, Novo Nordisk, Ypsomed, and Terumo.

View Analyst & Ambassador Comments
Go to original news
Jul 20,2023

IMA Medical Group Announces Partnership with Stability Health

IMA Medical Group (IMA) has announced its new partnership with Stability Health. IMA is offering the new IMA Diabetes Care Team, in partnership with Stability Health, which will provide advanced diabetes care to patients. According to IMA’s press release, this newly introduced diabetes care team is a virtual, customized care program designed to provide guidance and expert support to patients with diabetes.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jul 24,2023

Global Blood Glucose Monitoring System Market Size/Share Worth USD 31.34 Billion by 2030 at a 10.1% CAGR

According to a market research study published by the publisher, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 15.94 Billion in 2021 and is expected to reach USD 18.11 Billion in 2022 and is expected to reach around USD 31.34 Billion by 2030, at a CAGR of 10.1% between 2022 and 2030.

View Analyst & Ambassador Comments
Go to original news
Jul 24,2023 TOP STORY

Dario Launches Agreement with Large Regional Health Plan and Announces Preliminary Results for Second Quarter of 2023 as well as Business Update

DarioHealth announced today a new agreement with a large regional health plan to deliver highly personalized digital health solutions to more than 160,000 Plan members living with hypertension. The health plan is set to launch in late July 2023. Dario also announced today preliminary unaudited revenue results for the three months ended June 30, 2023 of between $6.0 million and $6.15 million, driven by growth in its Business-to-Business (B2B) sales channel, which has grown for the tenth quarter in a row due to the Company's strategic shift in resources. Revenue from strategic partnerships was less than expected in the second quarter due to fewer milestone deliveries than anticipated. Dario's preliminary unaudited revenues for the six months ended June 30, 2023 were between $13 million and $13.15 million, resulting from the expected reduction in direct sales to consumers that took place during the same period.

View Analyst & Ambassador Comments
Go to original news
Jul 25,2023

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Glucotrack, a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could reliably report glucose measurements for two years post-implant. Laboratory bench testing confirmed that a minimum two-year implant longevity is highly probable with the current sensor design. The implant longevity was independently verified by a third-party using sensor parameters to simulate sensor performance over time. Given the positive results of the study, the Company is now preparing for long-term animal studies, which are expected to begin later this year.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES